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Combination antiretroviral therapy for HIV infection improves immune function and eliminates the risk of
AIDS-related complications but does not restore full health. HIV-infected adults have excess risk of cardio-
vascular, liver, kidney, bone, and neurologic diseases. Many markers of inflammation are elevated in HIV
disease and strongly predictive of the risk of morbidity and mortality. A conceptual model has emerged to
explain this syndrome of diseases where HIV-mediated destruction of gut mucosa leads to local and
systemic inflammation. Translocated microbial products then pass through the liver, contributing to hepatic
damage, impairedmicrobial clearance, and impaired protein synthesis. Chronic activation of monocytes and
altered liver protein synthesis subsequently contribute to a hypercoagulable state. The combined effect of
systemic inflammation and excess clotting on tissue function leads to end-organ disease. Multiple therapeu-
tic interventions designed to reverse these pathways are now being tested in the clinic. It is likely that knowl-
edge gained on how inflammation affects health in HIV disease could have implications for our understanding
of other chronic inflammatory diseases and the biology of aging.Introduction
The natural history of both untreated and treated HIV infection is
well known. In the absence of antiretroviral drugs, persistent
high-level HIV replication causes progressive decline in CD4+
T cell counts, immunodeficiency, and AIDS. When the right com-
bination antiretroviral treatment regimen is given to a motivated
patient, HIV replication is essentially completely inhibited, lead-
ing over time to improved immune function and the near elimina-
tion of any risk for developing an AIDS-defining complication.
However, this does not mean that health is fully restored. For
reasons that are now the focus of intense research, effectively
treated HIV-infected adults have a greater risk of non-AIDS-
related overall morbidity and perhaps mortality than age-
matched HIV-uninfected adults. Cardiovascular disease,
neurocognitive disease, osteoporosis, liver disease, kidney
disease, and some cancers are more common in those with
HIV than in those without HIV (Freiberg et al., 2013). Because
many of these problems are generally associated with aging,
the concept that HIV somehow ‘‘accelerates’’ aging has caught
the attention of many in the community and the popular press.
Indeed, there are reports that frailty and other geriatric syn-
dromes occur years earlier than expected, at least in small sub-
set of patients (Desquilbet et al., 2007).
Several factors contribute to the excess risk of these non-AIDS
events, including antiretroviral drug toxicity, a high prevalence of
traditional risk factors (such as substance abuse, obesity, and
hypertension), and immune dysfunction and inflammation. The
literature with regard to the latter risk factor is remarkably consis-
tent. The frequency of ‘‘activated’’ T cells, inflammatory mono-
cytes, and inflammatory cytokines is higher in untreated and
treated HIV-infected adults than in age-matched uninfected
adults (French et al., 2009; Hunt et al., 2003; Neuhaus et al.,
2010; Sandler et al., 2011b). Biomarkers associated with a hy-percoagulable state are similarly elevated in HIV-infected adults
(Neuhaus et al., 2010). Importantly, subtle elevations in both
inflammatory and coagulation biomarkers are associated with
dramatic and sustained increases in risk of all-cause morbidity
andmortality, as compared to their prognostic effects in the gen-
eral population (Cushman et al., 1999; Kuller et al., 2008; Tien
et al., 2010).
In this Perspective, we discuss the mechanisms for chronic
inflammation in HIV disease, focusing on how these distinct
physiologic responses might be related. We also discuss how
inflammation and hypercoagulation might cause disease and
summarize ongoing attempts to alter these pathways therapeu-
tically. A testable model is presented in which HIV infection
directly and indirectly causes chronic activation of both the
adaptive and innate immune systems, resulting in a low-level
but sustained inflammatory state that persists even after the
virus is controlled with antiretroviral therapy. This sustained in-
flammatory state over decades causes vascular dyfunction
and alterations in coagulation state, leading to end-organ dis-
ease and eventually multimorbidity (Figure 1).
HIV as an Inflammatory Disease
Since the initial reports of AIDS, it has been clear that chronic
inflammation plays a central role in the pathogenesis of un-
treated HIV infection. Acute HIV infection is associatedwith rapid
and intense release of a variety of cytokines (including interferon-
a, interferon-g, inducible protein 10, tumor necrosis factor, IL-6,
IL-10, and IL-15) (Stacey et al., 2009). The frequency of activated
T cells also increases dramatically during acute HIV infection,
with up to 50% of certain CD8+ T subsets activated (Papagno
et al., 2004). After resolution of acute infection, a T cell activation
‘‘steady state’’ is achieved that is predicted in part by degree of
HIV replication and innate immune responses (Chevalier et al.,Immunity 39, October 17, 2013 ª2013 Elsevier Inc. 633
Figure 1. Pathogenesis of Inflammation-Associated Disease in HIV-Infected Adults
HIV infection causes damage to lymphoid and mucosa tissues, leading to progressive immunodeficiency, excess levels of pathogens (including HIV), and
inflammation. HIV also damages the mucosa of the gut, leading to microbial translocation. HIV and its treatment also affect liver function through a variety of
mechanisms. The collective effect of these initial insults is chronic monocyte and macrophage activation and hypercoagulation. These processes lead directly to
vascular harm, end-organ tissue damage, andmultimoribidity, all of which theoretically maymanifest later in life with the onset of a variety of geriatric syndromes.
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phenomenon has led to a number of conclusions regarding the
potential root causes of inflammation: (1) HIV replication contrib-
utes directly to T cell activation (however, the frequency of HIV-
specific T cells is only a small proportion of the activated cell
population, suggesting other less-direct mechanisms) (Papagno
et al., 2004); (2) other pathogens—including common herpes
viruses such as CMV—contribute to high level T cell activation,
although why the percentage of antigen-specific T cells is
dramatically elevated is not known (Doisne et al., 2004; Naeger
et al., 2010; Smith et al., 2013;Wittkop et al., 2013); (3) HIV-medi-
ated breakdown in the gut mucosa and chronic exposure to gut
microbial products like lipopolysaccharide (LPS) is also a key
factor driving inflammation (Brenchley et al., 2006); and (4)
dysfunctional immunoregulatory factors probably contribute to
persistent inflammation. This chronic inflammatory environment
appears to cause fibrosis in lymphoid tissues, which in turn
causes CD4+ T cell regenerative failure and disease (Figure 1;
Boulware et al., 2011; Schacker et al., 2002; Zeng et al., 2012).
Antiretroviral therapy partially reverses many if not all of these
proinflammatory pathways, but the effect is incomplete, and
inflammation persists indefinitely.634 Immunity 39, October 17, 2013 ª2013 Elsevier Inc.Given that CD4+ T cells are the main target for HIV infection,
it has long been assumed that abnormalities of the adaptive
immune system would dominate in any study of disease
pathogenesis. Indeed, the best-characterized biomarkers of
immune function in untreated HIV infection are the absolute
CD4+ T cell count and the frequency of activated T cells. This
assumption may not be valid in the context of treated HIV infec-
tion, where a growing number of studies have implicated mono-
cyte- and macrophage-related inflammation rather that T cell
activation as a predictor and presumable cause of disease
progression.
IL-6 is a broadly acting proinflammatory cytokine that is
released from a variety of cells, particularly monocytes andmac-
rophages. Antiretroviral-treated adults have on average about
40% to 60% higher concentrations of IL-6 than do well-matched
uninfected adults (Neuhaus et al., 2010). IL-6 amounts were
strongly associated with all-cause mortality in the INSIGHT Stra-
tegies for Management of Antiretroviral Therapy (SMART) study
(odds ratio for fourth versus first quartile of 8.3, p < 0.0001) (Kuller
et al., 2008). These findings have been confirmed in many other
studies, including the large ESPIRIT and SILCAAT cohorts (odds
ratio fourth/first quartile 5.6).
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cyte and macrophage activation. Both are elevated in HIV dis-
ease and predictive of morbidity and mortality (Burdo et al.,
2011b; Kelesidis et al., 2012; Sandler et al., 2011b). CD14 is
expressed on circulating monocytes and many tissue macro-
phages (although not those in the gut) and is the coreceptor,
along with TLR4, for LPS. LPS binding results in cleavage of
the GPI anchor of cell-surface CD14, the production of non-
GPI-linked CD14, and the release of both into the circulation as
soluble CD14 (sCD14). sCD14 can bind LPS and deliver it to a
variety of cell types, including vascular endothelial cells, thereby
allowing their activation by LPS. sCD14 is elevated in other
diseases characterized or exacerbated by endotoxemia, such
as hepatitis, rheumatoid arthritis, and systemic lupus erythema-
tosus. CD163 is the hemoglobin scavenger receptor expressed
on the surface of monocytes and macrophages, particularly
those that are more inflammatory (CD14+CD16+). It is released
as a soluble form (sCD163) in response to a number of inflamma-
tory signals, including binding of LPS to TLR4.
Abnormalities of the indoleamine 2,3-dioxygenase (IDO)
pathway also exist in HIV disease and are only partially reversed
by antiretroviral therapy. The ratio of kynurenine to tryptophan,
which reflects IDO activity, is elevated in untreated and treated
disease, is correlated with other inflammatory biomarkers, and
predicts disease progression independent of other pathways
(Boasso et al., 2007; Favre et al., 2010; P.W. Hunt et al., 2011,
IAS Conf. HIV Pathogenesis, Treatment, and Prevention, ab-
stract).
Monoctye turnover and activation have been directly linked to
SIV and HIV pathogenesis. SIV infection is associated with
increased turnover of circulating monoctyes, and the frequency
of these proliferating cells is correlated with sCD163, T cell acti-
vation, and risk of disease progression (Burdo et al., 2010; Hase-
gawa et al., 2009). The frequency of activated (CD14+CD16+)
monocytes is elevated in untreated and treated HIV disease
(Burdo et al., 2011a), whereas the frequency of proinflammatory
CD16+ monocytes in a largely treated cohort of HIV-infected
adults was independently associated with greater risk of coro-
nary artery calcium progression (J.V. Baker et al., 2013, CROI,
abstract).
Collectively, these data strongly indicate that chronic activa-
tion of innate immunity contributes to morbidity and mortality
in HIV-infected adults. Indeed, in those studies in which both
innate and T cell markers were measured, the former tended to
dominate in terms of the prognostic capacity (P. Hunt et al.,
2012, Conf. Retroviruses and Opportunistic Infections, abstract;
A. Tenorio et al., 2013, Conf. Retroviruses and Opportunistic In-
fections, abstract). A critical task for the field is to determine why
chronic upregulation of these pathways cause disease. Several
possibilities exist. Given that monocyte- and macrophage-
related inflammation is central to the formation of atherosclerosis
in the general population, much of the attention in the HIV
research community has shifted toward understanding how
these cells affect vascular health. Inflammation, altered blood
flow dynamics, circulating bacterial products, proatherogenic
lipids, and other factors associated with HIV infection can cause
damage to the endothelium and upregulation of adhesion fac-
tors. Monocytes are recruited, take up ‘‘residence’’ in blood
vessel walls, phagocytize lipids and other toxins, form foamcells, and contribute to the formation of atherosclerotic plaques.
When plaques become unstable or rupture, the coagulation pro-
cess is activated and thrombotic occlusion of the vessels oc-
curs, leading to tissue damage. This process is clearly not unique
to those with HIV infection (Libby et al., 2011; Woollard and
Geissmann, 2010), but may be accelerated by the chronic in-
flammatory nature of the disease. Chronic activation of the
innate immune system could also cause a potentially harmful hy-
percoagulable state, as outlined below.
Unique Role of Gut Mucosa in HIV Disease Pathogenesis
The gut mucosa contains a high concentration of HIV-suscepti-
ble, CCR5-expressing CD4+ T cells. During acute HIV infection,
the virus rapidly spreads throughout the gut-associated
lymphoid tissue (GALT), leading directly to the loss of CD4+
T cells and indirectly to epithelial injury (Brenchley et al., 2004;
Li et al., 2005; Sankaran et al., 2008). The resulting loss of
mucosal integrity results in sustained exposure within the gut
mucosa to proinflammatory microbial products (Figure 2). With
acute disease progression, microbial product translocation
and its inflammatory effects becomes systemic (Brenchley
et al., 2006; Burdo et al., 2011a; Hunt et al., 2012; Mehandru
et al., 2004). Effective antiretroviral therapy might temper this
process, particularly if initiated early, but the effect is incomplete
(Jiang et al., 2009; Mavigner et al., 2012; Mehandru et al., 2006).
In multiple observational studies of untreated and treated HIV
disease, plasma measures of microbial translocation such as
LPS, sCD14 (the LPS coreceptor), intestinal fatty acid binding
protein (I-FABP, a marker of gut epithelial cell apoptosis), and
zonulin (which declines in response to barrier disruption) have
been associated with disease progression (Ancuta et al., 2008;
French et al., 2013; Hunt et al., 2012; Kelesidis et al., 2012; Mar-
chetti et al., 2011; Sandler et al., 2011b). The role of microbial
translocation in disease pathogenesis has been confirmed in
experimental models of pathogenic SIV infection (Estes et al.,
2010).
Microbial translocation is not unique to HIV disease. Increased
intestinal permeability is a key factor in the pathogenesis of in-
flammatory bowel disease, pancreatitis, graft-versus-host dis-
ease, excessive alcohol consumption, and obesity and diabetes,
and might even contribute to aging (Lassenius et al., 2011;
Monte et al., 2012; Nalle and Turner, 2012; Pussinen et al.,
2007, 2011; Sandler et al., 2011a; Tran and Greenwood-Van
Meerveld, 2013). The proinflammatory products known to trans-
locate in such states include LPS, peptidoglycan, lipoteichoic
acid, flagellin, ribosomal DNA, and unmethylated CpG-contain-
ing DNA, all derived from bacteria and fungi. These products
cause both local and, after passing through the liver, systemic
effects via their stimulation of innate immune cells (particularly
macrophages and dendritic cells) and nonimmune cells
(including endothelial cells of the cardiovascular system) (Kanne-
ganti et al., 2007; Kawai and Akira, 2010).
What sets HIV disease apart from themany other conditions of
microbial translocation is that the damage to the gut mucosa is
2-fold—both immunologic and structural. Massive HIV-medi-
ated CD4+ T cell depletion is accompanied by enterocyte
apoptosis and lamina propria fibrosis (Brenchley et al., 2004; Li
et al., 2005; Sankaran et al., 2008). Furthermore, the preferential
loss of IL-17- and IL-22-secreting CD4+ T cells, which are criticalImmunity 39, October 17, 2013 ª2013 Elsevier Inc. 635
Figure 2. Impact of HIV on Gut Mucosa
The healthy gut mucosa is marked by functional
tight epithelial junctions and a highly regulated,
interrelated complex of dendritic cells, macro-
phages, neutrophils, and T cells. This system
generates protective mucus, antimicrobial pep-
tides, and secreted antibodies. Normal gut flora is
maintained and systemic exposure to microbes
and microbial products limited (top). HIV infection
alters most if not all aspects of gut defenses,
leading to breakdown in tight junctions, loss or
dysregulation of resident immune cells, alterations
in gut flora, and microbial translocation (bottom).
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mucosal surfaces, exacerbates and perpetuates this damage
(Brenchley et al., 2008; Favre et al., 2010). Inhibition of Th17
cell differentiation is further exacerbated by an upregulation of
tryptophan catabolism by the interferon- and microbial prod-
uct-inducible enzyme IDO. A vicious cycle has been proposed
in which microbial products such as LPS stimulate tissue-resi-
dent dendritic cells to produce interferon-alpha and activate
the IDO pathway, leading to a shift in T cells from Th17 cell
phenotype to T regulatory cell phenotype. This loss of Th17 cells
leads to even more microbial translocation, and the cycle con-
tinues (Favre et al., 2010).
HIV disease disrupts the normal microbiota of the gut (dysbio-
sis) (Ellis et al., 2011; Gori et al., 2008; Vujkovic-Cvijin et al.,
2013). This process is associated with an enrichment of bacterial
species that can catabolize tryptophan through the kynurenine
pathway, which may contribute to the loss of Th17 cells (Vuj-
kovic-Cvijin et al., 2013), as noted above. Although the effect636 Immunity 39, October 17, 2013 ª2013 Elsevier Inc.of bacterial metabolism on the gut im-
mune system needs to be more thor-
oughly characterized, it is tempting to
speculate on more far-reaching conse-
quences of dysbiosis in HIV infection.
For example, recent studies have shown
that metabolism of phosphatidylcholine
in the diet by components of the intestinal
microbiota results in the production of tri-
methylamine-N-oxide (TMAO), which has
potent proatherogenic effects (Koeth
et al., 2013; Tang et al., 2013). Given the
increased incidence of cardiovascular
disease in HIV-infected people (Freiberg
et al., 2013), associations between the in-
testinal microbiota and nonimmunologic
sequelae of HIV disease are clearly an
area ripe for investigation and a possible
target for therapeutic intervention.
Similar concerns have been raised
regarding enteric viral communities (‘‘vi-
rome’’). Pathogenic SIV infection is asso-
ciated with increased size and diversity of
the enteric virome (Handley et al., 2012),
and advanced HIV infection is associated
with increased size of the plasma virome
(Li et al., 2013). The clinical significance
of these changes has yet to be reported.Once microbial products, catabolites, and metabolites have
passed through the mucosa, they pass through the portal vein
into the liver. Sensing of microbial products by hepatocytes, he-
patic stellate cells, and Kupffer cells within the liver activates
proinflammatory and profibrotic pathways (Duffield et al., 2005;
Rivera et al., 2001; Seki et al., 2007; Su, 2002). Through mecha-
nisms yet to be defined, HIV reduces the number of Kupffer cells
and impairs hepatic function, thereby reducing the capacity of
the liver to mitigate the consequences of microbial translocation
(Balagopal et al., 2008, 2009; French et al., 2013; Sandler et al.,
2011a). The combined loss of mucosal immune surveillance and
hepatic impairment allows proinflammatory microbial products
to access the peripheral circulation and the organ systems it
supplies.
In summary, a unique ‘‘local’’ state exists in the gut in which
the virus, simply by rapidly depleting CD4+ T cells, destabilizes
the immunologic and structural integrity of epithelial barrier,
leading to microbial translocation, local inflammation, fibrosis,
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contributing to liver dysfunction and reduced clearance of these
same products (described below). Although the impact of this
process on inflammation in acute infection and in resource-
poor regions remains undefined and controversial (Chevalier
et al., 2013; Redd et al., 2009), the collective data from HIV
and general population literature strongly implicate this process
in the development of end-organ disease, including liver fibrosis
and cardiovascular disease. Once the process has been initi-
ated, each of the events associated with local mucosal damage
and microbial translocation both exacerbates and drives the
other such that even when virus replication is drastically reduced
by antiretroviral therapy, the process persists, preventing resto-
ration of health.
HIV also Causes a Hypercoagulable State, which Is
Linked to Inflammation and Risk of Disease
Abnormalities in coagulation factor levels in HIV-positive individ-
uals have been observed for more than 20 years (Bissuel et al.,
1992; Lijfering et al., 2008), and a hypercoagulable state was
proposed 10 years ago (Shen and Frenkel, 2004). The potential
role of hypercoagulability as a cause of morbidity and mortality
in HIV disease became more widely accepted after release of
the results from the aforementioned SMART study. In this large
clinical endpoint study, D-dimers—which are degradation prod-
ucts produced during clot lysis—yielded remarkably strong
associations with all-cause mortality, with an initial fully adjusted
fourth quartile odds ratio of approximately 40 (Kuller et al., 2008).
Follow-up in SMART and other studies have confirmed a strong
association of D-dimers with mortality and cardiovascular dis-
ease (Duprez et al., 2012). D-dimer also predicts venous throm-
boembolic disease (Jong et al., 2009; Musselwhite et al., 2011),
which is also increased in incidence in HIV-positive individuals
(Fultz et al., 2004). The association between D-dimers and
thromboembolic disease in the general population (e.g., with
oral contraception) is generally considered as evidence that hy-
percoagulation causes morbidity, and it is likely that the same
causal pathway applies to HIV disease.
HIV replication probably causes hypercoagulation and an in-
crease in D-dimer. The level of HIV replication is correlated
with D-dimer levels in untreated disease (Calmy et al., 2009; Kul-
ler et al., 2008) and the initiation of ART is associated with a
reduction in D-dimer (Jong et al., 2010; Palella et al., 2010)
although not to preinfection levels as judged by comparison
with noninfected controls. Intensification of apparently effective
antiretroviral therapy with an additional potent antiretroviral drug
decreases HIV replication even further and as a consequence
decreases D-dimer levels (Hatano et al., 2013b). HIV-associated
inflammation is alsoweakly associatedwith coagulation status in
some studies. Higher levels of sCD14 and sCD163 are correlated
with D-dimer levels (Funderburg et al., 2010; Jiang et al., 2009;
Pandrea et al., 2012), whereas IL-6 and CRP are associated
with D-dimer levels (Duprez et al., 2012; Justice et al., 2012).
Perhaps the most direct experimental evidence supporting a
causal link between microbial translocation, monocyte activa-
tion, hypercogulation, and disease comes from a series of
nonhuman primate studies. Despite comparable levels of viral
replication, SIV infection of its natural host (e.g., African green
monkeys) causes only transient inflammation and no hypercoa-gulation whereas SIV infection of susceptible hosts (e.g., pigtail
macaques) causes chronic inflammation and hypercoagulability
(Pandrea et al., 2012). Susceptible monkeys also developed
extensive in situ coagulopathies, with thrombi identified in the
kidney, lung, and brain among other organs. Infusion of LPS
into SIV-infected African green monkeys causes increased
macrophage activation (as defined by sCD14), increased coag-
ulation (as defined by D-dimer), and increased SIV replication,
providing a direct link between these various pathways (Pandrea
et al., 2012).
A growing number of human studies have linked microbial
translocation with hypercoagulation. As noted above, HIV-medi-
ated destruction of gut mucosa leads to chronic systemic
exposure to LPS. LPS binds to CD14 and TLR4, setting off a
cascade of cell activation and tissue factor expression (Funder-
burg et al., 2010). This in turn activates the coagulation cascade,
leading to increased risk of clotting. As described in the next
section, microbial translocation also affects liver function, which
has complex effects on coagulation system.
Given the observational nature of these studies, whether the
coagulopathy reflected by D-dimer levels is a causal component
of HIV pathophysiology remains unproven. Arguing in favor of
causality, D-dimer levels prospectively predict the occurrence
of both venous and arterial thrombosis in the general population
(Cushman et al., 1999, 2003) and in HIV-positive individuals
(Duprez et al., 2012; Ford et al., 2010; Jong et al., 2009; Ledwaba
et al., 2012; Musselwhite et al., 2011). Among HIV-infected
adults, D-dimer amounts add risk prediction to complex risk
algorithms such as the VACS Index (Justice et al., 2012). D-dimer
levels are associated with important intermediate pathophysio-
logical mechanisms such as endothelial damage and vascular
dysfunction (Baker et al., 2010; Hileman et al., 2012). Finally,
D-dimer levels are associated with in situ clot formation in SIV-
infected macaques (Pandrea et al., 2012). However, the defini-
tive answer to this question must await the gold standard of
randomized clinical trials of anticoagulation in HIV.
Inflammation, Liver Function, and Hyerpcoagulation
HIV infection may cause liver disease through several mecha-
nisms, including direct infection of stellate and Kupffer cells,
chronic inflammation, translocation of microbial products, and
low-grade disseminated coagulaopathy (Balagopal et al., 2009;
French et al., 2013; Peters et al., 2011; Tuyama et al., 2010).
This effect is exacerbated by chronic hepatitis C infection and
alcohol abuse, both common in HIV-infected adults (Weber
et al., 2006; Justice et al., 2010). Some commonly used antiretro-
viral drugs are potentially hepatoxic. The well-described meta-
bolic syndrome that is associated with antiretroviral therapy
probably impacts liver health. Biomarkers of liver fibrosis such
as hyaluronic acid and clinical estimates such as the FIB-4 are
elevated in untreated and treated HIV disease and are associ-
ated with mortality (Justice et al., 2012; Peters et al., 2011).
These observations collectively argue that hepatic function is a
critical determinant of health in HIV disease, although how he-
patic function influences nonliver outcomes is incomplete.
The liver produces a series of important coagulation factors.
Measurements of these factors in people have proven useful in
modeling the potential to produce thrombin (Baker et al.,
2013). Mathematical models of thrombin generation have beenImmunity 39, October 17, 2013 ª2013 Elsevier Inc. 637
Table 1. Anti-Inflammatory Agents for Management of Antiretroviral-Treated HIV Disease
Target Drug or Intervention
residual or cryptic HIV replication treatment intensification, optimized antiretroviral drug tissue penetration, novel antiretroviral drugs
excess copathogen burden valacyclovir (HSV), valganciclovir (CMV), HCV cure
microbial translocation sevelamer, rifaximin, mesalamine, isotretinoin, prebiotics, probiotics, colostrum
poor T cell function interleukin-7, growth hormone, anti-PD1 antibodies
lymphoid and tissue fibrosis perfenidone, ACE inhibitors, angiotensin II receptor blockers
chronic inflammation HMG CoA reductase inhibitors (‘‘statins’’), chloroquine, hydroxycloroquine, celecoxib (COX-2 inhibitors),
aspirin, methotrexate, lenalidomide, leflunomide, ruxolitinib (JAK inhibitors), sirolimus (mTOR inhibitors),
IDO inhibitors, anti-interferon-alpha antibodies, anti-IL-6 antibodies, anti-IL-1-beta antibodies
hypercoagulation aspirin, apixaban, dabigatran
cellular aging sirtuin activators, sirolimus
metabolic syndrome, obesity metformin, exercise, diet, vitamin D
Drugs aimed at reversing inflammation or its immediate consequences in antiretroviral-treated HIV infection are listed. Those drugs in more advanced
stages of development (phase I/II) are listed first, followed by those that are still in development.
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demonstrated substantive associations with prothrombotic
states such as coronary heart disease (Brummel-Ziedins,
2013). In a comprehensive study of pro- and anticoagulation fac-
tors within the tissue factor-mediated extrinsic pathway, we
found that HIV replication leads to short-term increases in
some procoagulants (e.g., factor VIII) and decreases both pro-
coagulants (e.g., prothrombin) and anticoagulants (e.g., anti-
thrombin, protein C). We then applied mathematical modeling
to estimate thrombin generation based on the composition of
extrinsic pathway factors (the ‘‘coagulome’’) and demonstrated
that the net effect of HIV replication was increased coagulation
potential, with a magnitude similar to that seen in the context
of acute coronary syndromes (Brummel-Ziedins, 2013).
There are many pathways by which chronic inflammation can
cause liver dysfunction and as a consequence affect coagulation
status. For example, untreated and treated HIV infection is asso-
ciated with chronic interferon-alpha signaling. This signaling is
presumably related to a number of factors, including HIV replica-
tion, excess loads of copathogens such as CMV, microbial
translocation, and dysbiosis. Chronic type I interferon signaling
is a well-accepted property of pathogenic HIV disease (Rotger
et al., 2011) and persists during effective antiretroviral therapy,
where it has negative effects on immune function and reconstitu-
tion (Fernandez et al., 2011; Herbeuval and Shearer, 2007).
Chronic interferon signaling can cause upregulation of double-
stranded RNA-dependent protein kinase (PKR), which is a cyto-
solic kinase whose activity results in the inhibition of cellular
mRNA translation, with a dramatic inhibition of global protein
synthesis (Pindel and Sadler, 2011; Stark et al., 1998). When
this global inhibition occurs in hepatocytes, the production of
coagulation factors would be expected to decline.
These observations collectively suggest that subtle alterations
in a precirrhotic liver function (resulting in part from chronic
inflammation) leads toahyercoagulable site andperhapsnonliver
end-organ disease. This hypothesis is being actively pursued in
the general, non-HIV population (Tripodi and Mannucci, 2011).
Clinical Trials of Anti-Inflammatory Drugs
The constellation of chronic diseases that disproportionately
affect the antiretroviral-treated HIV-infected population are all638 Immunity 39, October 17, 2013 ª2013 Elsevier Inc.strongly associated with inflammation in the general population.
Untangling if and how inflammation causes these diseases in
adults is the topic of intense research. Because many diseases
can either indirectly or directly contribute to an inflammatory
state (Justice et al., 2012), defining the cause and effect relation-
ships has been challenging. Indeed, in analysis of a large cohort
of US military veterans with and without HIV disease, controlling
for the presence of comorbidities such as cardiovascular
disease, hypertension, diabetes mellitus, hyperlipidemia, and
substance abuse attenuated the association between HIV infec-
tion and levels of IL-6, D-dimer, and sCD14 (Armah et al., 2012).
Even the association between clotting, inflammation, and dis-
ease is complex, because clotting can have a proinflammatory
effect and multimorbidity can lead to increased risk of clotting
(Engelmann and Massberg, 2013).
Most experts believe that a randomized clinical endpoint study
will be needed to definitively address the role of inflammation
and hypercoagulation as a cause of morbidity in HIV disease.
Before such expensive studies are undertaken, pilot studies
demonstrating that an intervention is safe and effective in
reducing inflammation are first required. Many such studies
have been completed or are ongoing; all are small and explor-
atory in nature (Table 1). The studies performed to date have
used a spectrum of endpoints, some poorly validated, which
limits the ability to draw any broad conclusions on what should
happen next.
An optimal way to manage inflammation would to be to
address its root cause(s). Given the central role of microbial
translocation in HIV disease pathogenesis, a number of studies
attempting to affect the gut microbiome and mucosa have
been performed. Bovine colostrum binds LPS and may prevent
its translocation, but had no effect in a randomized clinical trial
(Byakwaga et al., 2011). Prebiotics and probiotics, which alter
the bowel flora andmight reduce the quantity of potentially path-
ogenic bacteria, have been tested with positive early results in
nonhuman primate models (Klatt et al., 2013a) and humans
(Cahn et al., 2013; Gori et al., 2011). The combination of sulfasa-
lazine and rifaximin in nonhuman primates lowered microbial
translocation and inflammation, suggesting that antibiotics, if
given safely, could prove beneficial. Sevelamer binds LPS, has
showed promising results in nonhuman primates, and is being
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persuasive, but they collectively support future research in this
area.
Other root causes of inflammation include excess burden of
copathogens, persistent HIV production and replication, and
lymphoid fibrosis. Our group performed an intensive pathogen-
esis-oriented randomized clinical study and found that reducing
CMV replication with valganciclovir resulted in substantial reduc-
tion in T cell activation (Hunt et al., 2011). Studies aimed at HSV
are ongoing. One of themore unsettled areas of HIV investigation
pertains to whether HIV replication persists at low levels during
standard therapy. Two randomized clinical trials in which a
potent drug (raltegravir) was added to standard therapy (treat-
ment ‘‘intensification’’) found evidence that even during appar-
ently effective antiretroviral therapy the virus can continue to
replicate at very low levels and cause inflammation (Buzo´n
et al., 2010; Hatano et al., 2013b). Even in the absence of
ongoing cycles of virus replication, it is clear that virions are be-
ing constantly produced and released. The strong association
between reservoir size and activation during antiretroviral ther-
apy suggests that this reservoir may indeed have an inflamma-
tory effect (Hatano et al., 2013a; Klatt et al., 2013b). Finally,
because irreversible lymphoid tissue fibrosis has been impli-
cated in causing persistent immune dysregulation (Schacker
et al., 2002), drugs that reverse collagen deposition and/or
reverse fibrosis are being pursued. These drugs include angio-
tensin-converting enzyme (ACE) inhibitors and angiotensin re-
ceptor blockers (ARBs).
Another strategy is to reduce inflammation once the process
has been initiated. Again, a number of approaches have been
attempted. The statins have a well-accepted anti-inflammatory
effect, although the mechanism for this effect is unknown and
its role in preventing heart disease controversial. The use of sta-
tins has been associated with reduced levels of T cell activation
in untreated adults (Ganesan et al., 2011) and reduced levels of
activated monoctyes and sCD14 in treated adults (J.V. Baker
et al., 2013, CROI, abstract). Aspirin appears to reduce T cell
activation and sCD14 in treated adults (O’Brien et al., 2013).
COX-2 inhibitors may decrease inflammation in untreated adults
(Pettersen et al., 2011). Studies assessing the potential benefit of
methotrexate, anti-interleukin-6 antibodies, mTOR inhibitors
(e.g., sirolimus), and JAK1-JAK2 inhibitors are being planned.
Given the central role that hypercoagulation appears to have in
the pathogenesis of HIV disease, there is also growing interest in
looking at anticoagulants, although to our knowledge no study
has advanced into the clinic at this time (with the possible excep-
tion of aspirin). Possible drugs that might be considered include
dabigatran (anti-thrombin) and rivaroxaban (anti-factor Xa),
although drug-drug interactions and/or excess risk of bleeding
might prevent their use for HIV-associated hypercoagulation.
Of note, the statins, which might have a unique role in HIV dis-
ease (Moore et al., 2011), have known anticoagulant effects (Un-
das et al., 2005), arguing for their greater use in HIV disease.
Although many of the causes and consequences of inflamma-
tion that exist in the untreated state probably apply to the treated
disease stage, intervening with an anti-inflammatory drug in
these two distinct clinical conditions could be profoundly
different. For example, choroquine and hydroxychloroquine are
broadly activating anti-inflammatory drugs that have a numberof potential beneficial effects, including preventing TLR signaling
in dendritic cells. Although these drugs have shown potential
benefit in antiretroviral-treated adults (Piconi et al., 2011), a large
randomized clinical study of adults with early, untreated HIV
disease showed that they can actually increase HIV replication
and accelerate the loss of peripheral CD4+ T cell counts (Paton
et al., 2012), perhaps because the drug reduces the capacity
of immune system to control a very pathogenic virus. These
studies and theoretical considerations suggest that when block-
ing inflammation, the use of drugs that can maximally suppress
HIV replication may be needed.
There are a number of other barriers that will need to be over-
come if the field is to be advanced. Given the complexity of the
human immune system, any intervention designed to affect
one pathway will lead to an unpredictable effect on multiple
compensatory pathways. For example, our group recently per-
formed a limited-center, randomized, placebo-controlled study
of the CCR5 antagonist maraviroc in long-term treated adults
who had low CD4+ T cell counts. The primary hypothesis was
that by blocking CCR5, T cell chemotaxis to areas of inflamma-
tion might be prevented, resulting in less T cell activation. How-
ever, we observed an effect opposite to that predicted, with
indirect evidence from the study suggesting that compensatory
increases in the ligands for CCR5 causes direct proinflammatory
effects on macrophages (Hunt et al., 2013). This inherent
complexity makes the development of immune-based therapeu-
tics far more risky that the development of drugs that directly
target the pathogen, such as antiretroviral drugs.
A final barrier confronting the field is the lack of a validated sur-
rogate marker for inflammation and/or immune dysfunction. This
problem was well illustrated by the experience with interleukin-2
(IL-2) in HIV disease. Because no one questions the critical role
of peripheral CD4+ T cell declines in HIV disease, interventions
such as IL-2 that increase the number of these cells would be
expected to be beneficial, but in two large and expensive clinical
endpoint studies, IL-2 failed to provide any clinical benefit (it has
been postulated that IL-2-mediated increase in thrombosis risk
contributed to the failure of this intervention) (Abrams et al.,
2009). This sobering experience has, more than any other,
limited enthusiasm for developing drugs aimed at addressing
the limitations of current treatment strategies for HIV-infected
adults.
The Impact of Inflammation on Morbidity May Be Age
Dependent
It has been argued that humans evolved to remain robust until
what is now considered ‘‘middle age.’’ Throughout much of
recent human history, procreation and protection of the family
ended by the fifth decade of life, an age at which many of the
consequences of chronic inflammatory diseases start to
become more readily apparent (De Martinis et al., 2005; Finch,
2007; Vasto et al., 2007). CMV infection, for example, is a
chronic inflammatory infection that dramatically reshapes the
adaptive immune system (Sylwester et al., 2005) but has no
appreciable effect on health in the young and middle-aged.
Once more advanced age is reached, the presence of CMV
as a risk factor for age-associated complications such as frailty
becomes more readily apparent, with CMV-associated changes
to immune function being a likely mediator of disease in theseImmunity 39, October 17, 2013 ª2013 Elsevier Inc. 639
Figure 3. Impact of HIV on Inflammation, Coagulation, and Health
Root causes of inflammation in HIV disease include damage to gutmucosa and lymphoid systems, which cause exposure tomicrobes and high pathogen burden.
Microbial translocation, inflammation, HIV replication, and other factors contribute to liver dysfunction, which in turn leads to reduced clearance of microbial
products and altered production of critical hepatic proteins. Liver dysfunction and chronic activation of innate immunity leads to a hypercoagulable state. Excess
subclinical clotting and inflammation each contribute to end-organ tissue damage, vascular disease, and a variety of diseases. The cumulative effect of these
pathways in combination with other well-accepted risk factors for biologic and clinical aging is expected to affect health in older age.
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prove to be true in HIV disease. CD8+ T cell activation, for
example, had no appreciable effect on disease progression in
a large cohort of largely young adults but had an effect in a
post-hoc analysis of those over the age of 50 (Lok et al., 2013).
The capacity of humans to compensate for many insults is a
central concept in studies of healthy aging. Most organ systems
exhibit some degree of redundancy, and many of the geriatric
syndromes associated with reduced function (e.g., frailty, falls,
immobility, and incontinence) emerge only when several sys-
tems are affected. Isolated harm to single systems manifesting
as liver disease, kidney disease, bone disease, and neuropathy
has consequences in isolation, but their true effect on long-
term health may become apparent only late in life when this
redundancy begins to decline (Clegg et al., 2013). The fact that
HIV infection and its treatment are associated with a series of
biologic factors (e.g., inflammation, immune dysfunction, telo-
merase inhibition, mitochondria dysfunction), clinical factors
(e.g., polypharmacy, multimorbidity), and social factors (e.g., so-
cial isolation, poverty) that influence aging suggest that a global
population of well-treated individuals will confront unique chal-640 Immunity 39, October 17, 2013 ª2013 Elsevier Inc.lenges when older (Figure 3; Deeks, 2011; Justice, 2010;
Lo´pez-Otı´n et al., 2013).
The impact that chronic low-level inflammation will have on the
global population of antiretroviral-treated adults who are now
expected to live for decades is not known. Notably, the spectrum
of inflammatory and coagulation abnormalities described in
largely middle-aged HIV-infected populations (e.g., elevated
D-dimer, IL-6, T cell activation, and monocyte activation) shares
a number of striking similarities with that observed in much older
noninfected adults, where they are known to predict morbidity
andmortality (Cesari et al., 2003; Singh andNewman, 2011;Wal-
ston et al., 2002). Prospective clinical trials aimed at defining
whether anti-inflammatory interventions are beneficial will need
to consider the possibility that the cumulative consequences of
inflammation on health may become apparent only when partic-
ipants are older.
The potential link between age, inflammation, microbial trans-
location, liver function, and multimorbidity was recently high-
lighted in a comprehensive study of young versus old mice.
LPS exposure in old (but not young) mice causes release from
macrophages of harmful levels of proinflammatory cytokines
Immunity
Perspective(including IL-6), which in turn causes liver damage and eventually
multiorgan failure (Bouchlaka et al., 2013).
Concluding Remarks
HIV was identified as the cause of AIDS in 1983. Since that time,
billions of dollars have been invested in the determining how the
virus is spread and how it causes disease. We probably know
more about the pathogenesis of this disease than that of any
other chronic infection. With the advent of highly effective antire-
troviral therapy, the nature of HIV disease has largely shifted from
one of immunodeficiency to one of chronic inflammation,
although we recognize that these two phenomena are tightly
linked in both untreated and treated disease. As the cohorts of
well-treated individuals become more robust, it is becoming
increasingly clear that HIV infection is now a chronic inflamma-
tory disease and that the disease shares a remarkable similarity
to a number of other inflammatory noninfectious diseases.
We believe that the disparate data spanning many disciplines
reviewed here support a model that that could be used to inform
future translational research. HIV replication initiates an inflam-
matory process during acute infection that is driven directly by
viral replication and indirectly by (1) excess levels of translocated
microbial products, (2) excess levels of other chronic pathogens,
including CMV, (3) loss of immunoregulatory responses, and (4)
potentially by hypercoagulability. Effective antiretroviral therapy
reduces HIV replication to negligible levels, but the virus persists
and is chronically produced at low levels. The mucosal damage
brought on by HIV is incompletely reversed and microbial trans-
location continues indefinitely. Lymphoid damage is also only
partially reversed by therapy, resulting in a state of indefinite
immunodeficiency. The collective outcome of these pathways
is a persistent inflammatory and/or hypercoagulable state that
could in some people persist indefinitely, even as HIV replication
is largely controlled by antiretroviral therapy (Figure 3). Because
HIV infection is largely a disease of the young, it is possible that
some people (including most concerningly the pediatric popula-
tion) might be exposed to such a state for several decades. The
many clinical trial and observational studies summarized here
suggest but do not prove that persistent low-level inflammation
is causing harm to many tissues. If this harm proves to be cumu-
lative, then even mild changes might over time lead to progres-
sive deterioration organ function, with clinical manifestations
becoming increasingly apparent as people age. Characterizing
the pathogenesis of this process and identifying novel therapies
to prevent or reverse inflammation and hypercoagulation will be
necessary if the health of HIV-infected individuals is to be fully
restored.
ACKNOWLEDGMENTS
This work was supported by grants from the National Institute of Allergy and
Infectious Diseases (K24 AI069994), the DARE: Delaney AIDS Research Enter-
prise (DARE; U19AI096109), and the Intramural Program of the National Insti-
tute of Allergy and Infectious Diseases.
REFERENCES
Abrams, D., Le´vy, Y., Losso, M.H., Babiker, A., Collins, G., Cooper, D.A.,
Darbyshire, J., Emery, S., Fox, L., Gordin, F., et al.; INSIGHT-ESPRIT Study
Group; SILCAAT Scientific Committee. (2009). Interleukin-2 therapy in patients
with HIV infection. N. Engl. J. Med. 361, 1548–1559.Ancuta, P., Kamat, A., Kunstman, K.J., Kim, E.Y., Autissier, P., Wurcel, A.,
Zaman, T., Stone, D., Mefford, M., Morgello, S., et al. (2008). Microbial trans-
location is associated with increased monocyte activation and dementia in
AIDS patients. PLoS ONE 3, e2516.
Armah, K.A., McGinnis, K., Baker, J., Gibert, C., Butt, A.A., Bryant, K.J., Goetz,
M., Tracy, R., Oursler, K.K., Rimland, D., et al. (2012). HIV status, burden of
comorbid disease, and biomarkers of inflammation, altered coagulation, and
monocyte activation. Clin. Infect. Dis. 55, 126–136.
Baker, J., Quick, H., Hullsiek, K.H., Tracy, R., Duprez, D., Henry, K., and Nea-
ton, J.D. (2010). Interleukin-6 and d-dimer levels are associated with vascular
dysfunction in patients with untreated HIV infection. HIV Med. 11, 608–609.
Baker, J.V., Brummel-Ziedins, K., Neuhaus, J., Duprez, D., Cummins, N.,
Dalmau, D., Dehovitz, J., Lehmann, C., Sullivan, A., Woolley, I., et al.; INSIGHT
SMART Study Team. (2013). HIV replication alters the composition of extrinsic
pathway coagulation factors and increases thrombin generation. J. Am. Heart
Assoc. 2, e000264.
Balagopal, A., Philp, F.H., Astemborski, J., Block, T.M., Mehta, A., Long, R.,
Kirk, G.D., Mehta, S.H., Cox, A.L., Thomas, D.L., and Ray, S.C. (2008). Human
immunodeficiency virus-related microbial translocation and progression of
hepatitis C. Gastroenterology 135, 226–233.
Balagopal, A., Ray, S.C., De Oca, R.M., Sutcliffe, C.G., Vivekanandan, P.,
Higgins, Y., Mehta, S.H., Moore, R.D., Sulkowski, M.S., Thomas, D.L., and
Torbenson, M.S. (2009). Kupffer cells are depleted with HIV immunodeficiency
and partially recovered with antiretroviral immune reconstitution. AIDS 23,
2397–2404.
Bissuel, F., Berruyer, M., Causse, X., Dechavanne, M., and Trepo, C. (1992).
Acquired protein S deficiency: correlation with advanced disease in HIV-1-in-
fected patients. J. Acquir. Immune Defic. Syndr. 5, 484–489.
Boasso, A., Herbeuval, J.P., Hardy, A.W., Anderson, S.A., Dolan, M.J., Fuchs,
D., and Shearer, G.M. (2007). HIV inhibits CD4+ T-cell proliferation by inducing
indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood 109,
3351–3359.
Bouchlaka, M.N., Sckisel, G.D., Chen, M., Mirsoian, A., Zamora, A.E., Mavera-
kis, E., Wilkins, D.E.C., Alderson, K.L., Hsiao, H.H., Weiss, J.M., et al. (2013).
Aging predisposes to acute inflammatory induced pathology after tumor
immunotherapy. J. Exp. Med. Published online September 30, 2013. http://
dx.doi.org/10.1084/jem.20131219.
Boulware, D.R., Hullsiek, K.H., Puronen, C.E., Rupert, A., Baker, J.V., French,
M.A., Bohjanen, P.R., Novak, R.M., Neaton, J.D., and Sereti, I.; INSIGHT Study
Group. (2011). Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before
initiation of antiretroviral therapy (ART) are associated with increased risk of
AIDS or death. J. Infect. Dis. 203, 1637–1646.
Brenchley, J.M., Schacker, T.W., Ruff, L.E., Price, D.A., Taylor, J.H., Beilman,
G.J., Nguyen, P.L., Khoruts, A., Larson, M., Haase, A.T., and Douek, D.C.
(2004). CD4+ T cell depletion during all stages of HIV disease occurs predom-
inantly in the gastrointestinal tract. J. Exp. Med. 200, 749–759.
Brenchley, J.M., Price, D.A., Schacker, T.W., Asher, T.E., Silvestri, G., Rao, S.,
Kazzaz, Z., Bornstein, E., Lambotte, O., Altmann, D., et al. (2006). Microbial
translocation is a cause of systemic immune activation in chronic HIV infection.
Nat. Med. 12, 1365–1371.
Brenchley, J.M., Paiardini, M., Knox, K.S., Asher, A.I., Cervasi, B., Asher, T.E.,
Scheinberg, P., Price, D.A., Hage, C.A., Kholi, L.M., et al. (2008). Differential
Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infec-
tions. Blood 112, 2826–2835.
Brummel-Ziedins, K. (2013). Models for thrombin generation and risk of
disease. J. Thromb. Haemost. 11(Suppl 1 ), 212–223.
Burdo, T.H., Soulas, C., Orzechowski, K., Button, J., Krishnan, A., Sugimoto,
C., Alvarez, X., Kuroda, M.J., and Williams, K.C. (2010). Increased monocyte
turnover from bone marrow correlates with severity of SIV encephalitis and
CD163 levels in plasma. PLoS Pathog. 6, e1000842.
Burdo, T.H., Lentz, M.R., Autissier, P., Krishnan, A., Halpern, E., Letendre, S.,
Rosenberg, E.S., Ellis, R.J., and Williams, K.C. (2011a). Soluble CD163 made
by monocyte/macrophages is a novel marker of HIV activity in early and
chronic infection prior to and after anti-retroviral therapy. J. Infect. Dis. 204,
154–163.Immunity 39, October 17, 2013 ª2013 Elsevier Inc. 641
Immunity
PerspectiveBurdo, T.H., Lo, J., Abbara, S., Wei, J., DeLelys, M.E., Preffer, F., Rosenberg,
E.S., Williams, K.C., andGrinspoon, S. (2011b). Soluble CD163, a novel marker
of activated macrophages, is elevated and associated with noncalcified coro-
nary plaque in HIV-infected patients. J. Infect. Dis. 204, 1227–1236.
Buzo´n, M.J., Massanella, M., Llibre, J.M., Esteve, A., Dahl, V., Puertas, M.C.,
Gatell, J.M., Domingo, P., Paredes, R., Sharkey, M., et al. (2010). HIV-1 repli-
cation and immune dynamics are affected by raltegravir intensification of
HAART-suppressed subjects. Nat. Med. 16, 460–465.
Byakwaga, H., Kelly, M., Purcell, D.F., French, M.A., Amin, J., Lewin, S.R.,
Haskelberg, H., Kelleher, A.D., Garsia, R., Boyd, M.A., et al.; CORAL Study
Group. (2011). Intensification of antiretroviral therapy with raltegravir or addi-
tion of hyperimmune bovine colostrum in HIV-infected patients with subopti-
mal CD4+ T-cell response: a randomized controlled trial. J. Infect. Dis. 204,
1532–1540.
Cahn, P., Ruxrungtham, K., Gazzard, B., Diaz, R.S., Gori, A., Kotler, D.P., Vrie-
sema, A., Georgiou, N.A., Garssen, J., Clerici, M., and Lange, J.M.; Blinded
Nutritional Study for Immunity and Tolerance Evaluation Study Team. (2013).
The immunomodulatory nutritional intervention NR100157 reduced CD4+ T-
cell decline and immune activation: a 1-year multicenter randomized
controlled double-blind trial in HIV-infected persons not receiving antiretroviral
therapy (The BITE Study). Clin. Infect. Dis. 57, 139–146.
Calmy, A., Gayet-Ageron, A., Montecucco, F., Nguyen, A., Mach, F., Burger,
F., Ubolyam, S., Carr, A., Ruxungtham, K., Hirschel, B., and Ananworanich,
J.; STACCATO Study Group. (2009). HIV increases markers of cardiovascular
risk: results from a randomized, treatment interruption trial. AIDS 23, 929–939.
Cesari, M., Penninx, B.W., Newman, A.B., Kritchevsky, S.B., Nicklas, B.J.,
Sutton-Tyrrell, K., Tracy, R.P., Rubin, S.M., Harris, T.B., and Pahor, M.
(2003). Inflammatory markers and cardiovascular disease (The Health, Aging
and Body Composition [Health ABC] Study). Am. J. Cardiol. 92, 522–528.
Chevalier, M.F., Petitjean, G., Dunyach-Re´my, C., Didier, C., Girard, P.M.,
Manea, M.E., Campa, P., Meyer, L., Rouzioux, C., Lavigne, J.P., et al.
(2013). The Th17/Treg ratio, IL-1RA and sCD14 levels in primary HIV infection
predict the T-cell activation set point in the absence of systemic microbial
translocation. PLoS Pathog. 9, e1003453.
Clegg, A., Young, J., Iliffe, S., Rikkert, M.O., and Rockwood, K. (2013). Frailty in
elderly people. Lancet 381, 752–762.
Cushman, M., Lemaitre, R.N., Kuller, L.H., Psaty, B.M., Macy, E.M., Sharrett,
A.R., and Tracy, R.P. (1999). Fibrinolytic activation markers predict myocardial
infarction in the elderly. The Cardiovascular Health Study. Arterioscler.
Thromb. Vasc. Biol. 19, 493–498.
Cushman, M., Folsom, A.R., Wang, L., Aleksic, N., Rosamond, W.D., Tracy,
R.P., and Heckbert, S.R. (2003). Fibrin fragment D-dimer and the risk of future
venous thrombosis. Blood 101, 1243–1248.
De Martinis, M., Franceschi, C., Monti, D., and Ginaldi, L. (2005). Inflamm-
ageing and lifelong antigenic load as major determinants of ageing rate and
longevity. FEBS Lett. 579, 2035–2039.
Deeks, S.G. (2011). HIV infection, inflammation, immunosenescence, and
aging. Annu. Rev. Med. 62, 141–155.
Deeks, S.G., Kitchen, C.M., Liu, L., Guo, H., Gascon, R., Narva´ez, A.B., Hunt,
P., Martin, J.N., Kahn, J.O., Levy, J., et al. (2004). Immune activation set point
during early HIV infection predicts subsequent CD4+ T-cell changes indepen-
dent of viral load. Blood 104, 942–947.
Desquilbet, L., Jacobson, L.P., Fried, L.P., Phair, J.P., Jamieson, B.D., Hollo-
way, M., and Margolick, J.B.; Multicenter AIDS Cohort Study. (2007). HIV-1
infection is associated with an earlier occurrence of a phenotype related to
frailty. J. Gerontol. A Biol. Sci. Med. Sci. 62, 1279–1286.
Doisne, J.M., Urrutia, A., Lacabaratz-Porret, C., Goujard, C., Meyer, L., Chaix,
M.L., Sinet, M., and Venet, A. (2004). CD8+ T cells specific for EBV, cytomeg-
alovirus, and influenza virus are activated during primary HIV infection.
J. Immunol. 173, 2410–2418.
Duffield, J.S., Forbes, S.J., Constandinou, C.M., Clay, S., Partolina, M.,
Vuthoori, S., Wu, S., Lang, R., and Iredale, J.P. (2005). Selective depletion of
macrophages reveals distinct, opposing roles during liver injury and repair.
J. Clin. Invest. 115, 56–65.
Duprez, D.A., Neuhaus, J., Kuller, L.H., Tracy, R., Belloso, W., De Wit, S.,
Drummond, F., Lane, H.C., Ledergerber, B., Lundgren, J., et al.; INSIGHT642 Immunity 39, October 17, 2013 ª2013 Elsevier Inc.SMART Study Group. (2012). Inflammation, coagulation and cardiovascular
disease in HIV-infected individuals. PLoS ONE 7, e44454.
Ellis, C.L., Ma, Z.M., Mann, S.K., Li, C.S., Wu, J., Knight, T.H., Yotter, T.,
Hayes, T.L., Maniar, A.H., Troia-Cancio, P.V., et al. (2011). Molecular charac-
terization of stool microbiota in HIV-infected subjects by panbacterial and
order-level 16S ribosomal DNA (rDNA) quantification and correlations with
immune activation. J. Acquir. Immune Defic. Syndr. 57, 363–370.
Engelmann, B., and Massberg, S. (2013). Thrombosis as an intravascular
effector of innate immunity. Nat. Rev. Immunol. 13, 34–45.
Estes, J.D., Harris, L.D., Klatt, N.R., Tabb, B., Pittaluga, S., Paiardini, M.,
Barclay, G.R., Smedley, J., Pung, R., Oliveira, K.M., et al. (2010). Damaged in-
testinal epithelial integrity linked to microbial translocation in pathogenic sim-
ian immunodeficiency virus infections. PLoS Pathog. 6, e1001052.
Favre, D., Mold, J., Hunt, P.W., Kanwar, B., Loke, P., Seu, L., Barbour, J.D.,
Lowe, M.M., Jayawardene, A., Aweeka, F., et al. (2010). Tryptophan catabo-
lism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulato-
ry T cells in HIV disease. Sci. Transl. Med. 2, 32ra36.
Fernandez, S., Tanaskovic, S., Helbig, K., Rajasuriar, R., Kramski, M., Murray,
J.M., Beard, M., Purcell, D., Lewin, S.R., Price, P., and French, M.A. (2011).
CD4+ T-cell deficiency in HIV patients responding to antiretroviral therapy is
associated with increased expression of interferon-stimulated genes in
CD4+ T cells. J. Infect. Dis. 204, 1927–1935.
Finch, C.E. (2007). The Biology of Human Longevity. (Amsterdam: Elsevier).
Ford, E.S., Greenwald, J.H., Richterman, A.G., Rupert, A., Dutcher, L., Badral-
maa, Y., Natarajan, V., Rehm, C., Hadigan, C., and Sereti, I. (2010). Traditional
risk factors and D-dimer predict incident cardiovascular disease events in
chronic HIV infection. AIDS 24, 1509–1517.
Freiberg, M.S., Chang, C.C., Kuller, L.H., Skanderson, M., Lowy, E., Kraemer,
K.L., Butt, A.A., Bidwell Goetz, M., Leaf, D., Oursler, K.A., et al. (2013). HIV
infection and the risk of acute myocardial infarction. JAMA Intern. Med. 173,
614–622.
French, M.A., King, M.S., Tschampa, J.M., da Silva, B.A., and Landay, A.L.
(2009). Serum immune activation markers are persistently increased in
patients with HIV infection after 6 years of antiretroviral therapy despite
suppression of viral replication and reconstitution of CD4+ T cells. J. Infect.
Dis. 200, 1212–1215.
French, A.L., Evans, C.T., Agniel, D.M., Cohen, M.H., Peters, M., Landay, A.L.,
and Desai, S.N. (2013). Microbial translocation and liver disease progression in
women coinfected with HIV and hepatitis C virus. J. Infect. Dis. 208, 679–689.
Fultz, S.L., McGinnis, K.A., Skanderson, M., Ragni, M.V., and Justice, A.C.
(2004). Association of venous thromboembolism with human immunodefi-
ciency virus and mortality in veterans. Am. J. Med. 116, 420–423.
Funderburg, N.T., Mayne, E., Sieg, S.F., Asaad, R., Jiang, W., Kalinowska, M.,
Luciano, A.A., Stevens, W., Rodriguez, B., Brenchley, J.M., et al. (2010).
Increased tissue factor expression on circulating monocytes in chronic HIV
infection: relationship to in vivo coagulation and immune activation. Blood
115, 161–167.
Ganesan, A., Crum-Cianflone, N., Higgins, J., Qin, J., Rehm, C., Metcalf, J.,
Brandt, C., Vita, J., Decker, C.F., Sklar, P., et al. (2011). High dose atorvastatin
decreases cellular markers of immune activation without affecting HIV-1 RNA
levels: results of a double-blind randomized placebo controlled clinical trial.
J. Infect. Dis. 203, 756–764.
Gori, A., Tincati, C., Rizzardini, G., Torti, C., Quirino, T., Haarman, M., Ben
Amor, K., van Schaik, J., Vriesema, A., Knol, J., et al. (2008). Early impairment
of gut function and gut flora supporting a role for alteration of gastrointestinal
mucosa in human immunodeficiency virus pathogenesis. J. Clin. Microbiol. 46,
757–758.
Gori, A., Rizzardini, G., Van’t Land, B., Amor, K.B., van Schaik, J., Torti, C.,
Quirino, T., Tincati, C., Bandera, A., Knol, J., et al. (2011). Specific prebiotics
modulate gut microbiota and immune activation in HAART-naive HIV-infected
adults: results of the ‘‘COPA’’ pilot randomized trial. Mucosal Immunol. 4,
554–563.
Handley, S.A., Thackray, L.B., Zhao, G., Presti, R., Miller, A.D., Droit, L.,
Abbink, P., Maxfield, L.F., Kambal, A., Duan, E., et al. (2012). Pathogenic sim-
ian immunodeficiency virus infection is associated with expansion of the
enteric virome. Cell 151, 253–266.
Immunity
PerspectiveHasegawa, A., Liu, H., Ling, B., Borda, J.T., Alvarez, X., Sugimoto, C., Vinet-
Oliphant, H., Kim, W.K., Williams, K.C., Ribeiro, R.M., et al. (2009). The level
of monocyte turnover predicts disease progression in the macaque model of
AIDS. Blood 114, 2917–2925.
Hatano, H., Jain, V., Hunt, P.W., Lee, T.H., Sinclair, E., Do, T.D., Hoh, R.,
Martin, J.N., McCune, J.M., Hecht, F., et al. (2013a). Cell-based measures of
viral persistence are associated with immune activation and programmed
cell death protein 1 (PD-1)-expressing CD4+ T cells. J. Infect. Dis. 208, 50–56.
Hatano, H., Strain, M.C., Scherzer, R., Bacchetti, P., Wentworth, D., Hoh, R.,
Martin, J.N., McCune, J.M., Neaton, J.D., Tracy, R., et al. (2013b). Increase
in 2-LTR circles and decrease in D-dimer after raltegravir intensification in
treated HIV-infected patients: a randomized, placebo-controlled trial.
J. Infect. Dis. Published online September 18, 2013. http://dx.doi.org/10.
1093/infdis/jit453.
Herbeuval, J.P., and Shearer, G.M. (2007). HIV-1 immunopathogenesis: how
good interferon turns bad. Clin. Immunol. 123, 121–128.
Hileman, C.O., Longenecker, C.T., Carman, T.L., Milne, G.L., Labbato, D.E.,
Storer, N.J., White, C.A., and McComsey, G.A. (2012). Elevated D-dimer is
independently associated with endothelial dysfunction: a cross-sectional
study in HIV-infected adults on antiretroviral therapy. Antivir. Ther. (Lond.)
17, 1345–1349.
Hunt, P.W., Martin, J.N., Sinclair, E., Bredt, B., Hagos, E., Lampiris, H., and
Deeks, S.G. (2003). T cell activation is associated with lower CD4+ T cell gains
in human immunodeficiency virus-infected patients with sustained viral
suppression during antiretroviral therapy. J. Infect. Dis. 187, 1534–1543.
Hunt, P.W., Martin, J.N., Sinclair, E., Epling, L., Teague, J., Jacobson, M.A.,
Tracy, R.P., Corey, L., and Deeks, S.G. (2011). Valganciclovir reduces T cell
activation in HIV-infected individuals with incomplete CD4+ T cell recovery
on antiretroviral therapy. J. Infect. Dis. 203, 1474–1483.
Hunt, P.W., Shulman, N.S., Hayes, T.L., Dahl, V., Somsouk, M., Funderburg,
N.T., McLaughlin, B., Landay, A.L., Adeyemi, O., Gilman, L.E., et al. (2013).
The immunologic effects of maraviroc intensification in treated HIV-infected
individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood
121, 4635–4646.
Jiang, W., Lederman, M.M., Hunt, P., Sieg, S.F., Haley, K., Rodriguez, B.,
Landay, A., Martin, J., Sinclair, E., Asher, A.I., et al. (2009). Plasma levels of
bacterial DNA correlate with immune activation and the magnitude of immune
restoration in persons with antiretroviral-treated HIV infection. J. Infect. Dis.
199, 1177–1185.
Jong, E., Louw, S., Meijers, J.C., de Kruif, M.D., ten Cate, H., Bu¨ller, H.R.,
Mulder, J.W., and van Gorp, E.C. (2009). The hemostatic balance in HIV-in-
fected patients with and without antiretroviral therapy: partial restoration
with antiretroviral therapy. AIDS Patient Care STDS 23, 1001–1007.
Jong, E., Louw, S., van Gorp, E.C., Meijers, J.C., ten Cate, H., and Jacobson,
B.F. (2010). The effect of initiating combined antiretroviral therapy on endothe-
lial cell activation and coagulation markers in South African HIV-infected indi-
viduals. Thromb. Haemost. 104, 1228–1234.
Justice, A.C. (2010). HIV and aging: time for a new paradigm. Curr. HIV/AIDS
Rep. 7, 69–76.
Justice, A., Sullivan, L., and Fiellin, D. (2010). HIV/AIDS, comorbidity, and
alcohol. Alcohol Res. Health 33, 258–266.
Justice, A.C., Freiberg, M.S., Tracy, R., Kuller, L., Tate, J.P., Goetz, M.B.,
Fiellin, D.A., Vanasse, G.J., Butt, A.A., Rodriguez-Barradas, M.C., et al.;
VACS Project Team. (2012). Does an index composed of clinical data reflect
effects of inflammation, coagulation, and monocyte activation on mortality
among those aging with HIV? Clin. Infect. Dis. 54, 984–994.
Kanneganti, T.D., Lamkanfi, M., and Nu´n˜ez, G. (2007). Intracellular NOD-like
receptors in host defense and disease. Immunity 27, 549–559.
Kawai, T., and Akira, S. (2010). The role of pattern-recognition receptors in
innate immunity: update on Toll-like receptors. Nat. Immunol. 11, 373–384.
Kelesidis, T., Kendall, M.A., Yang, O.O., Hodis, H.N., and Currier, J.S. (2012).
Biomarkers of microbial translocation andmacrophage activation: association
with progression of subclinical atherosclerosis in HIV-1 infection. J. Infect. Dis.
206, 1558–1567.
Klatt, N.R., Canary, L.A., Sun, X., Vinton, C.L., Funderburg, N.T., Morcock,
D.R., Quin˜ones, M., Deming, C.B., Perkins, M., Hazuda, D.J., et al. (2013a).Probiotic/prebiotic supplementation of antiretrovirals improves gastrointes-
tinal immunity in SIV-infected macaques. J. Clin. Invest. 123, 903–907.
Klatt, N.R., Chomont, N., Douek, D.C., and Deeks, S.G. (2013b). Immune acti-
vation and HIV persistence: implications for curative approaches to HIV infec-
tion. Immunol. Rev. 254, 326–342.
Koch, S., Larbi, A., Ozcelik, D., Solana, R., Gouttefangeas, C., Attig, S., Wikby,
A., Strindhall, J., Franceschi, C., and Pawelec, G. (2007). Cytomegalovirus
infection: a driving force in human T cell immunosenescence. Ann. N Y
Acad. Sci. 1114, 23–35.
Koeth, R.A., Wang, Z., Levison, B.S., Buffa, J.A., Org, E., Sheehy, B.T., Britt,
E.B., Fu, X., Wu, Y., Li, L., et al. (2013). Intestinal microbiota metabolism of
L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19,
576–585.
Kuller, L.H., Tracy, R., Belloso, W., De Wit, S., Drummond, F., Lane, H.C.,
Ledergerber, B., Lundgren, J., Neuhaus, J., Nixon, D., et al.; INSIGHT SMART
Study Group. (2008). Inflammatory and coagulation biomarkers and mortality
in patients with HIV infection. PLoS Med. 5, e203.
Lassenius, M.I., Pietila¨inen, K.H., Kaartinen, K., Pussinen, P.J., Syrja¨nen, J.,
Forsblom, C., Po¨rsti, I., Rissanen, A., Kaprio, J., Mustonen, J., et al.; FinnDiane
StudyGroup. (2011). Bacterial endotoxin activity in human serum is associated
with dyslipidemia, insulin resistance, obesity, and chronic inflammation.
Diabetes Care 34, 1809–1815.
Ledwaba, L., Tavel, J.A., Khabo, P., Maja, P., Qin, J., Sangweni, P., Liu, X.,
Follmann, D., Metcalf, J.A., Orsega, S., et al.; Project Phidisa Biomarkers
Team. (2012). Pre-ART levels of inflammation and coagulation markers are
strong predictors of death in a South African cohort with advanced HIV
disease. PLoS ONE 7, e24243.
Li, Q., Duan, L., Estes, J.D., Ma, Z.M., Rourke, T.,Wang, Y., Reilly, C., Carlis, J.,
Miller, C.J., and Haase, A.T. (2005). Peak SIV replication in resting memory
CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 434, 1148–
1152.
Li, L., Deng, X., Linsuwanon, P., Bangsberg, D., Bwana, M.B., Hunt, P., Martin,
J.N., Deeks, S.G., and Delwart, E. (2013). AIDS alters the commensal plasma
virome. J. Virol. 87, 10912–10915.
Libby, P., Ridker, P.M., and Hansson, G.K. (2011). Progress and challenges in
translating the biology of atherosclerosis. Nature 473, 317–325.
Lijfering, W.M., Sprenger, H.G., Georg, R.R., van derMeulen, P.A., and van der
Meer, J. (2008). Relationship between progression to AIDS and thrombophilic
abnormalities in HIV infection. Clin. Chem. 54, 1226–1233.
Lok, J.J., Hunt, P.W.o., Collier, A.C., Benson, C.A., Witt, M.D., Luque, A.E.,
Deeks, S.G., and Bosch, R.J. (2013). The impact of age on the prognostic
capacity of CD8+ T-cell activation during suppressive antiretroviral therapy.
AIDS. Published online August 24, 2013. http://dx.doi.org/10.1097/QAD.
0b013e32836191b1.
Lo´pez-Otı´n, C., Blasco, M.A., Partridge, L., Serrano, M., and Kroemer, G.
(2013). The hallmarks of aging. Cell 153, 1194–1217.
Marchetti, G., Cozzi-Lepri, A., Merlini, E., Bellistrı`, G.M., Castagna, A., Galli,
M., Verucchi, G., Antinori, A., Costantini, A., Giacometti, A., et al.; ICONA
Foundation Study Group. (2011). Microbial translocation predicts disease
progression of HIV-infected antiretroviral-naive patients with high CD4+ cell
count. AIDS 25, 1385–1394.
Mavigner, M., Cazabat, M., Dubois, M., L’Faqihi, F.E., Requena, M., Pasquier,
C., Klopp, P., Amar, J., Alric, L., Barange, K., et al. (2012). Altered CD4+ T cell
homing to the gut impairs mucosal immune reconstitution in treated HIV-in-
fected individuals. J. Clin. Invest. 122, 62–69.
Mehandru, S., Poles, M.A., Tenner-Racz, K., Horowitz, A., Hurley, A., Hogan,
C., Boden, D., Racz, P., and Markowitz, M. (2004). Primary HIV-1 infection is
associated with preferential depletion of CD4+ T lymphocytes from effector
sites in the gastrointestinal tract. J. Exp. Med. 200, 761–770.
Mehandru, S., Poles, M.A., Tenner-Racz, K., Jean-Pierre, P., Manuelli, V.,
Lopez, P., Shet, A., Low, A.,Mohri, H., Boden, D., et al. (2006). Lack of mucosal
immune reconstitution during prolonged treatment of acute and early HIV-1
infection. PLoS Med. 3, e484.
Monte, S.V., Caruana, J.A., Ghanim, H., Sia, C.L., Korzeniewski, K., Schentag,
J.J., and Dandona, P. (2012). Reduction in endotoxemia, oxidative and inflam-
matory stress, and insulin resistance after Roux-en-Y gastric bypass surgery inImmunity 39, October 17, 2013 ª2013 Elsevier Inc. 643
Immunity
Perspectivepatients with morbid obesity and type 2 diabetes mellitus. Surgery 151,
587–593.
Moore, R.D., Bartlett, J.G., and Gallant, J.E. (2011). Association between use
of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS
ONE 6, e21843.
Musselwhite, L.W., Sheikh, V., Norton, T.D., Rupert, A., Porter, B.O., Penzak,
S.R., Skinner, J., Mican, J.M., Hadigan, C., and Sereti, I. (2011). Markers of
endothelial dysfunction, coagulation and tissue fibrosis independently predict
venous thromboembolism in HIV. AIDS 25, 787–795.
Naeger, D.M., Martin, J.N., Sinclair, E., Hunt, P.W., Bangsberg, D.R., Hecht, F.,
Hsue, P., McCune, J.M., and Deeks, S.G. (2010). Cytomegalovirus-specific
T cells persist at very high levels during long-term antiretroviral treatment of
HIV disease. PLoS ONE 5, e8886.
Nalle, S.C., and Turner, J.R. (2012). Endothelial and epithelial barriers in graft-
versus-host disease. Adv. Exp. Med. Biol. 763, 105–131.
Nesheim,M.E., Tracy, R.P., andMann, K.G. (1984). ‘‘Clotspeed,’’ a mathemat-
ical simulation of the functional properties of prothrombinase. J. Biol. Chem.
259, 1447–1453.
Neuhaus, J., Jacobs, D.R., Jr., Baker, J.V., Calmy, A., Duprez, D., La Rosa, A.,
Kuller, L.H., Pett, S.L., Ristola, M., Ross, M.J., et al. (2010). Markers of inflam-
mation, coagulation, and renal function are elevated in adults with HIV infec-
tion. J. Infect. Dis. 201, 1788–1795.
O’Brien, M., Montenont, E., Hu, L., Nardi, M.A., Valdes, V., Merolla, M., Getten-
berg, G., Cavanagh, K., Aberg, J.A., Bhardwaj, N., and Berger, J.S. (2013).
Aspirin attenuates platelet activation and immune activation in HIV-1-infected
subjects on antiretroviral therapy: a pilot study. J. Acquir. Immune Defic.
Syndr. 63, 280–288.
Palella, F.J., Jr., Gange, S.J., Benning, L., Jacobson, L., Kaplan, R.C., Landay,
A.L., Tracy, R.P., and Elion, R. (2010). Inflammatory biomarkers and abacavir
use in the Women’s Interagency HIV Study and the Multicenter AIDS Cohort
Study. AIDS 24, 1657–1665.
Pandrea, I., Cornell, E., Wilson, C., Ribeiro, R.M., Ma, D., Kristoff, J., Xu, C.,
Haret-Richter, G.S., Trichel, A., Apetrei, C., et al. (2012). Coagulation
biomarkers predict disease progression in SIV-infected nonhuman primates.
Blood 120, 1357–1366.
Papagno, L., Spina, C.A., Marchant, A., Salio, M., Rufer, N., Little, S., Dong, T.,
Chesney, G., Waters, A., Easterbrook, P., et al. (2004). Immune activation and
CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol.
2, E20.
Paton, N.I., Goodall, R.L., Dunn, D.T., Franzen, S., Collaco-Moraes, Y.,
Gazzard, B.G., Williams, I.G., Fisher, M.J., Winston, A., Fox, J., et al.; Hydrox-
ychloroquine Trial Team. (2012). Effects of hydroxychloroquine on immune
activation and disease progression among HIV-infected patients not receiving
antiretroviral therapy: a randomized controlled trial. JAMA 308, 353–361.
Peters, L., Neuhaus, J., Mocroft, A., Soriano, V., Rockstroh, J., Dore, G., Puoti,
M., Tedaldi, E., Clotet, B., Kupfer, B., et al.; SMART Study Group. (2011).
Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-co-
infected persons interrupting antiretroviral therapy in the SMART Study. Anti-
vir. Ther. (Lond.) 16, 667–675.
Pettersen, F.O., Torheim, E.A., Dahm, A.E., Aaberge, I.S., Lind, A., Holm, M.,
Aandahl, E.M., Sandset, P.M., Taske´n, K., and Kvale, D. (2011). An exploratory
trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated
immune activation and improved T cell-dependent vaccine responses.
J. Virol. 85, 6557–6566.
Piconi, S., Parisotto, S., Rizzardini, G., Passerini, S., Terzi, R., Argenteri, B.,
Meraviglia, P., Capetti, A., Biasin, M., Trabattoni, D., and Clerici, M. (2011).
Hydroxychloroquine drastically reduces immune activation in HIV-infected,
antiretroviral therapy-treated immunologic nonresponders. Blood 118, 3263–
3272.
Pindel, A., and Sadler, A. (2011). The role of protein kinase R in the interferon
response. J. Interferon Cytokine Res. 31, 59–70.
Pussinen, P.J., Tuomisto, K., Jousilahti, P., Havulinna, A.S., Sundvall, J., and
Salomaa, V. (2007). Endotoxemia, immune response to periodontal patho-
gens, and systemic inflammation associate with incident cardiovascular
disease events. Arterioscler. Thromb. Vasc. Biol. 27, 1433–1439.644 Immunity 39, October 17, 2013 ª2013 Elsevier Inc.Pussinen, P.J., Havulinna, A.S., Lehto, M., Sundvall, J., and Salomaa, V.
(2011). Endotoxemia is associated with an increased risk of incident diabetes.
Diabetes Care 34, 392–397.
Redd, A.D., Dabitao, D., Bream, J.H., Charvat, B., Laeyendecker, O., Kiwa-
nuka, N., Lutalo, T., Kigozi, G., Tobian, A.A., Gamiel, J., et al. (2009). Microbial
translocation, the innate cytokine response, and HIV-1 disease progression in
Africa. Proc. Natl. Acad. Sci. USA 106, 6718–6723.
Rivera, C.A., Bradford, B.U., Hunt, K.J., Adachi, Y., Schrum, L.W., Koop, D.R.,
Burchardt, E.R., Rippe, R.A., and Thurman, R.G. (2001). Attenuation of CCl(4)-
induced hepatic fibrosis by GdCl(3) treatment or dietary glycine. Am. J. Phys-
iol. Gastrointest. Liver Physiol. 281, G200–G207.
Rotger, M., Dalmau, J., Rauch, A., McLaren, P., Bosinger, S.E., Martinez, R.,
Sandler, N.G., Roque, A., Liebner, J., Battegay, M., et al. (2011). Comparative
transcriptomics of extreme phenotypes of human HIV-1 infection and SIV
infection in sooty mangabey and rhesus macaque. J. Clin. Invest. 121,
2391–2400.
Sandler, N.G., Koh, C., Roque, A., Eccleston, J.L., Siegel, R.B., Demino, M.,
Kleiner, D.E., Deeks, S.G., Liang, T.J., Heller, T., and Douek, D.C. (2011a).
Host response to translocated microbial products predicts outcomes of
patients with HBV or HCV infection. Gastroenterology 141, 1220–1230, e1–e3.
Sandler, N.G., Wand, H., Roque, A., Law, M., Nason, M.C., Nixon, D.E., Ped-
ersen, C., Ruxrungtham, K., Lewin, S.R., Emery, S., et al.; INSIGHT SMART
Study Group. (2011b). Plasma levels of soluble CD14 independently predict
mortality in HIV infection. J. Infect. Dis. 203, 780–790.
Sankaran, S., George,M.D., Reay, E., Guadalupe, M., Flamm, J., Prindiville, T.,
and Dandekar, S. (2008). Rapid onset of intestinal epithelial barrier dysfunction
in primary human immunodeficiency virus infection is driven by an imbalance
between immune response and mucosal repair and regeneration. J. Virol. 82,
538–545.
Schacker, T.W., Nguyen, P.L., Beilman, G.J., Wolinsky, S., Larson, M., Reilly,
C., and Haase, A.T. (2002). Collagen deposition in HIV-1 infected lymphatic
tissues and T cell homeostasis. J. Clin. Invest. 110, 1133–1139.
Seki, E., DeMinicis, S., Osterreicher, C.H., Kluwe, J., Osawa, Y., Brenner, D.A.,
and Schwabe, R.F. (2007). TLR4 enhances TGF-beta signaling and hepatic
fibrosis. Nat. Med. 13, 1324–1332.
Shen, Y.M., and Frenkel, E.P. (2004). Thrombosis and a hypercoagulable state
in HIV-infected patients. Clin. Appl. Thromb. Hemost. 10, 277–280.
Singh, T., and Newman, A.B. (2011). Inflammatory markers in population
studies of aging. Ageing Res. Rev. 10, 319–329.
Smith, M.Z., Bastidas, S., Karrer, U., and Oxenius, A. (2013). Impact of antigen
specificity onCD4+ T cell activation in chronic HIV-1 infection. BMC Infect. Dis.
13, 100.
Stacey, A.R., Norris, P.J., Qin, L., Haygreen, E.A., Taylor, E., Heitman, J., Leb-
edeva, M., DeCamp, A., Li, D., Grove, D., et al. (2009). Induction of a striking
systemic cytokine cascade prior to peak viremia in acute human immunodefi-
ciency virus type 1 infection, in contrast to more modest and delayed
responses in acute hepatitis B and C virus infections. J. Virol. 83, 3719–3733.
Stark, G.R., Kerr, I.M., Williams, B.R., Silverman, R.H., and Schreiber, R.D.
(1998). How cells respond to interferons. Annu. Rev. Biochem. 67, 227–264.
Su, G.L. (2002). Lipopolysaccharides in liver injury: molecular mechanisms of
Kupffer cell activation. Am. J. Physiol. Gastrointest. Liver Physiol. 283, G256–
G265.
Sylwester, A.W., Mitchell, B.L., Edgar, J.B., Taormina, C., Pelte, C., Ruchti, F.,
Sleath, P.R., Grabstein, K.H., Hosken, N.A., Kern, F., et al. (2005). Broadly
targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate
the memory compartments of exposed subjects. J. Exp. Med. 202, 673–685.
Tang,W.H., Wang, Z., Levison, B.S., Koeth, R.A., Britt, E.B., Fu, X., Wu, Y., and
Hazen, S.L. (2013). Intestinal microbial metabolism of phosphatidylcholine and
cardiovascular risk. N. Engl. J. Med. 368, 1575–1584.
Tien, P.C., Choi, A.I., Zolopa, A.R., Benson, C., Tracy, R., Scherzer, R.,
Bacchetti, P., Shlipak, M., and Grunfeld, C. (2010). Inflammation and mortality
in HIV-infected adults: analysis of the FRAM study cohort. J. Acquir. Immune
Defic. Syndr. 55, 316–322.
Immunity
PerspectiveTran, L., and Greenwood-Van Meerveld, B. (2013). Age-associated remodel-
ing of the intestinal epithelial barrier. J. Gerontol. A Biol. Sci. Med. Sci. 68,
1045–1056.
Tripodi, A., and Mannucci, P.M. (2011). The coagulopathy of chronic liver
disease. N. Engl. J. Med. 365, 147–156.
Tuyama, A.C., Hong, F., Saiman, Y., Wang, C., Ozkok, D., Mosoian, A., Chen,
P., Chen, B.K., Klotman, M.E., and Bansal, M.B. (2010). Human immunodefi-
ciency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen
I and monocyte chemoattractant protein-1 expression: implications for the
pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology 52,
612–622.
Undas, A., Brummel-Ziedins, K.E., and Mann, K.G. (2005). Statins and blood
coagulation. Arterioscler. Thromb. Vasc. Biol. 25, 287–294.
Vasto, S., Candore, G., Balistreri, C.R., Caruso, M., Colonna-Romano, G.,
Grimaldi, M.P., Listi, F., Nuzzo, D., Lio, D., and Caruso, C. (2007). Inflammatory
networks in ageing, age-related diseases and longevity. Mech. Ageing Dev.
128, 83–91.
Vujkovic-Cvijin, I., Dunham, R.M., Iwai, S., Maher, M.C., Albright, R.G., Broad-
hurst, M.J., Hernandez, R.D., Lederman, M.M., Huang, Y., Somsouk, M., et al.
(2013). Dysbiosis of the gut microbiota is associated with hiv disease progres-
sion and tryptophan catabolism. Sci. Transl. Med. 5, 93ra91.Walston, J., McBurnie, M.A., Newman, A., Tracy, R.P., Kop,W.J., Hirsch, C.H.,
Gottdiener, J., and Fried, L.P.; Cardiovascular Health Study. (2002). Frailty and
activation of the inflammation and coagulation systems with and without clin-
ical comorbidities: results from the Cardiovascular Health Study. Arch. Intern.
Med. 162, 2333–2341.
Weber, R., Sabin, C.A., Friis-Møller, N., Reiss, P., El-Sadr, W.M., Kirk, O.,
Dabis, F., Law, M.G., Pradier, C., De Wit, S., et al. (2006). Liver-related deaths
in persons infected with the human immunodeficiency virus: the D:A:D study.
Arch. Intern. Med. 166, 1632–1641.
Wittkop, L., Bitard, J., Lazaro, E., Neau, D., Bonnet, F., Mercie, P., Dupon, M.,
Hessamfar, M., Ventura, M., Malvy, D., et al.; Groupe d’Epide´miologie Clinique
du SIDA en Aquitaine. (2013). Effect of cytomegalovirus-induced immune
response, self antigen-induced immune response, and microbial translocation
on chronic immune activation in successfully treated HIV type 1-infected
patients: the ANRS CO3 Aquitaine Cohort. J. Infect. Dis. 207, 622–627.
Woollard, K.J., and Geissmann, F. (2010). Monocytes in atherosclerosis:
subsets and functions. Nat. Rev. Cardiol. 7, 77–86.
Zeng, M., Southern, P.J., Reilly, C.S., Beilman, G.J., Chipman, J.G., Schacker,
T.W., and Haase, A.T. (2012). Lymphoid tissue damage in HIV-1 infection
depletes naı¨ve T cells and limits T cell reconstitution after antiretroviral therapy.
PLoS Pathog. 8, e1002437.Immunity 39, October 17, 2013 ª2013 Elsevier Inc. 645
